Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoid Heart Disease | 3 | 2023 | 12 | 2.250 |
Why?
|
| Echocardiography | 10 | 2021 | 1182 | 1.840 |
Why?
|
| Neuroendocrine Tumors | 2 | 2023 | 634 | 1.040 |
Why?
|
| Heart Ventricles | 4 | 2018 | 846 | 0.940 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 2023 | 39 | 0.890 |
Why?
|
| Heart Diseases | 5 | 2022 | 732 | 0.880 |
Why?
|
| Ventricular Function, Left | 2 | 2016 | 603 | 0.870 |
Why?
|
| Neoplasms | 19 | 2022 | 15193 | 0.790 |
Why?
|
| Carcinoid Tumor | 1 | 2023 | 280 | 0.780 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 2195 | 0.740 |
Why?
|
| Erythropoietin | 1 | 2021 | 205 | 0.730 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 1162 | 0.720 |
Why?
|
| Endocarditis | 1 | 2021 | 125 | 0.720 |
Why?
|
| Stroke Volume | 3 | 2016 | 577 | 0.660 |
Why?
|
| Erdheim-Chester Disease | 1 | 2018 | 53 | 0.650 |
Why?
|
| Catheters, Indwelling | 1 | 2021 | 374 | 0.650 |
Why?
|
| Anemia | 2 | 2021 | 689 | 0.600 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 548 | 0.600 |
Why?
|
| Tachycardia, Sinus | 1 | 2016 | 12 | 0.590 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 672 | 0.530 |
Why?
|
| Cardiotoxicity | 7 | 2022 | 155 | 0.530 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 251 | 0.500 |
Why?
|
| Thrombosis | 2 | 2018 | 781 | 0.500 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 435 | 0.480 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 610 | 0.460 |
Why?
|
| Recovery of Function | 1 | 2016 | 703 | 0.440 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2022 | 342 | 0.440 |
Why?
|
| Takotsubo Cardiomyopathy | 3 | 2021 | 53 | 0.390 |
Why?
|
| Quality Improvement | 1 | 2016 | 851 | 0.350 |
Why?
|
| Heart Failure | 5 | 2020 | 2516 | 0.330 |
Why?
|
| Cultural Diversity | 1 | 2008 | 76 | 0.310 |
Why?
|
| Pericardial Effusion | 2 | 2019 | 118 | 0.280 |
Why?
|
| Antineoplastic Agents | 7 | 2019 | 14289 | 0.280 |
Why?
|
| Cardiology | 2 | 2022 | 530 | 0.260 |
Why?
|
| Coronary Artery Disease | 3 | 2022 | 1011 | 0.260 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 353 | 0.250 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 14889 | 0.230 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2018 | 435 | 0.230 |
Why?
|
| Humans | 37 | 2023 | 261506 | 0.220 |
Why?
|
| Drug-Eluting Stents | 2 | 2021 | 131 | 0.220 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2022 | 50 | 0.200 |
Why?
|
| Risk Factors | 8 | 2022 | 17523 | 0.200 |
Why?
|
| Everolimus | 1 | 2023 | 415 | 0.190 |
Why?
|
| Acute Coronary Syndrome | 2 | 2022 | 259 | 0.190 |
Why?
|
| Early Diagnosis | 2 | 2019 | 298 | 0.180 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2019 | 46 | 0.170 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 403 | 0.170 |
Why?
|
| Cardiologists | 1 | 2019 | 33 | 0.170 |
Why?
|
| Pericardiocentesis | 1 | 2019 | 33 | 0.170 |
Why?
|
| Survival Rate | 4 | 2021 | 12221 | 0.170 |
Why?
|
| Texas | 4 | 2021 | 6311 | 0.170 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2021 | 314 | 0.160 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2018 | 66 | 0.160 |
Why?
|
| Heart Arrest | 1 | 2022 | 358 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2019 | 303 | 0.150 |
Why?
|
| Echocardiography, Doppler | 1 | 2018 | 180 | 0.150 |
Why?
|
| Electrocardiography | 3 | 2017 | 1145 | 0.150 |
Why?
|
| Oncologists | 1 | 2019 | 134 | 0.150 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2018 | 160 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 698 | 0.140 |
Why?
|
| Systole | 1 | 2016 | 196 | 0.140 |
Why?
|
| Pericarditis, Constrictive | 1 | 2016 | 11 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2018 | 145 | 0.140 |
Why?
|
| Academies and Institutes | 1 | 2016 | 95 | 0.140 |
Why?
|
| Incidence | 3 | 2021 | 5673 | 0.140 |
Why?
|
| Middle Aged | 12 | 2021 | 86204 | 0.140 |
Why?
|
| Morbidity | 1 | 2017 | 397 | 0.140 |
Why?
|
| Cardiac Tamponade | 1 | 2016 | 51 | 0.140 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 267 | 0.130 |
Why?
|
| Machine Learning | 3 | 2022 | 319 | 0.130 |
Why?
|
| Heart Valve Prosthesis | 1 | 2019 | 386 | 0.130 |
Why?
|
| Medical Oncology | 2 | 2022 | 1423 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2016 | 161 | 0.130 |
Why?
|
| Male | 15 | 2021 | 123000 | 0.130 |
Why?
|
| Cardiotonic Agents | 1 | 2016 | 151 | 0.130 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 550 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 462 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 846 | 0.120 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 476 | 0.120 |
Why?
|
| Contrast Media | 1 | 2020 | 1472 | 0.120 |
Why?
|
| Female | 14 | 2022 | 141928 | 0.120 |
Why?
|
| ROC Curve | 1 | 2016 | 1183 | 0.110 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 833 | 0.110 |
Why?
|
| Global Health | 1 | 2017 | 657 | 0.100 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2012 | 62 | 0.100 |
Why?
|
| Amyloidosis | 1 | 2014 | 176 | 0.100 |
Why?
|
| Primary Myelofibrosis | 1 | 2020 | 831 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2021 | 37905 | 0.100 |
Why?
|
| Chest Pain | 1 | 2012 | 155 | 0.100 |
Why?
|
| Mass Screening | 1 | 2019 | 1509 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 4320 | 0.100 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 62 | 0.100 |
Why?
|
| Biomarkers | 2 | 2019 | 5047 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2017 | 1824 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.090 |
Why?
|
| Aged | 8 | 2021 | 70117 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8865 | 0.080 |
Why?
|
| Adult | 7 | 2022 | 77950 | 0.080 |
Why?
|
| Quality of Life | 1 | 2021 | 4532 | 0.070 |
Why?
|
| Coronary Angiography | 2 | 2022 | 598 | 0.070 |
Why?
|
| Inflammation | 1 | 2017 | 2522 | 0.070 |
Why?
|
| Prognosis | 4 | 2019 | 21713 | 0.070 |
Why?
|
| Prevalence | 2 | 2020 | 3260 | 0.070 |
Why?
|
| Hospitalization | 2 | 2022 | 2083 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 6009 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2022 | 1274 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2019 | 3341 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 4757 | 0.060 |
Why?
|
| Patient Discharge | 1 | 2008 | 661 | 0.060 |
Why?
|
| Sex Factors | 1 | 2008 | 2139 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 6100 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7702 | 0.050 |
Why?
|
| Amino Acid Transport System A | 1 | 2001 | 11 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2022 | 32848 | 0.050 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2021 | 48 | 0.050 |
Why?
|
| Absorbable Implants | 1 | 2021 | 65 | 0.050 |
Why?
|
| Proline | 1 | 2001 | 130 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2001 | 330 | 0.040 |
Why?
|
| Polymers | 1 | 2021 | 223 | 0.040 |
Why?
|
| Defibrillators | 1 | 2019 | 25 | 0.040 |
Why?
|
| Aorta, Abdominal | 1 | 2020 | 152 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 6915 | 0.040 |
Why?
|
| Coronary Restenosis | 1 | 2019 | 63 | 0.040 |
Why?
|
| Myocarditis | 1 | 2021 | 190 | 0.040 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2019 | 69 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2019 | 71 | 0.040 |
Why?
|
| Age Factors | 1 | 2008 | 5377 | 0.040 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 128 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2022 | 6869 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 235 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 15694 | 0.040 |
Why?
|
| Aspirin | 1 | 2021 | 455 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 444 | 0.040 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 343 | 0.040 |
Why?
|
| Inpatients | 1 | 2022 | 678 | 0.040 |
Why?
|
| Dyspnea | 1 | 2020 | 416 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 860 | 0.040 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 221 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2001 | 1130 | 0.030 |
Why?
|
| Coronary Disease | 1 | 2020 | 764 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2008 | 9244 | 0.030 |
Why?
|
| Length of Stay | 1 | 2022 | 1900 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2019 | 581 | 0.030 |
Why?
|
| United States | 2 | 2022 | 15433 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2020 | 1271 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2016 | 329 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 2352 | 0.030 |
Why?
|
| Amyloid | 1 | 2014 | 97 | 0.030 |
Why?
|
| Endovascular Procedures | 1 | 2019 | 516 | 0.030 |
Why?
|
| Survivors | 1 | 2017 | 1031 | 0.020 |
Why?
|
| Exercise Test | 1 | 2012 | 312 | 0.020 |
Why?
|
| Hepcidins | 1 | 2011 | 34 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 4892 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 2961 | 0.020 |
Why?
|
| Hypertension | 1 | 2020 | 1503 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 4053 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 1052 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2019 | 1374 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 2803 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1819 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 7551 | 0.020 |
Why?
|
| Animals | 3 | 2019 | 59536 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 4744 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 2001 | 131 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 21445 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2001 | 549 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 869 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2001 | 292 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 29902 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 31252 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 2049 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 3639 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 4938 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 5637 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 6086 | 0.010 |
Why?
|